Our CTX therapy is a cell-based treatment for CLI patients, which, in pre-clinical studies, has shown the potential to restore sufficient blood flow in the affected lower limb to avoid amputation, and therefore the severe health consequences that typically result from such a procedure. The trial is being undertaken through NHS Tayside at Ninewells Hospital and Medical School, Dundee, Scotland. In this dose escalation safety study, the CTX cells were administered via straightforward intramuscular injection into the affected lower limb of nine patients with peripheral arterial disease (CLI is the end-stage of this disease).
We have completed recruitment in a UK Phase I clinical trial of our CTX cell therapy in limb ischaemia patients. with no significant adverse safety events reported post-administration of the CTX cells via intramuscular injections. Long term safety data is expected in H1 2018.
We recently announced that we had put our CLI programme on hold in order to focus on the significant opportunity presented by our stroke disability programme and our expanded retinal disease programmes.
Further information regarding our clinical trials, including relevant contact details, may be found on clinicaltrials.gov.